Supercharge Your Innovation With Domain-Expert AI Agents!

Tipiracil intermediate compound

A technology for tipiracil and intermediates, applied in the field of drug synthesis, can solve the problems of difficult to pass the target product and low yield, and achieve the effect of being suitable for industrial production, easy to operate, and improving safety

Pending Publication Date: 2020-12-04
LUNAN PHARMA GROUP CORPORATION
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0022] In summary, in the reported technical methods for preparing tipiracil, the main problem is that the target product is easily hydrolyzed to produce impurity D, which makes the target product difficult to pass, or the yield is low after repeated refining

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tipiracil intermediate compound
  • Tipiracil intermediate compound
  • Tipiracil intermediate compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Add SM-1 (9.75g, 50mmol) and SM-2 (18.30g, 62.5mmol) into methanol (80mL), until the materials are completely dissolved, add dropwise a solution of DBU (24.36g, 160mmol) dissolved in methanol (30mL) , the dropwise addition is completed, the temperature is controlled at 45-50°C for 14 hours, the reaction solution is filtered while it is hot, the filtrate is cooled to 0-5°C, stirred and crystallized for 2-3 hours, filtered with suction, and the obtained filter cake is vacuum-dried to obtain the pyrazidine intermediate Compound I, yield 93.5%, purity 99.88%.

Embodiment 2

[0067] Add SM-1 (9.75g, 50mmol) and SM-2 (16.10g, 55.0mmol) into methanol (80mL), until the materials are completely dissolved, add dropwise a solution of DBU (30.45g, 200mmol) dissolved in methanol (30mL) , the dropwise addition is completed, the temperature is controlled at 45-50°C for 14 hours, the reaction solution is filtered while it is hot, the filtrate is cooled to 0-5°C, stirred and crystallized for 2-3 hours, filtered with suction, and the obtained filter cake is vacuum-dried to obtain the pyrazidine intermediate Compound I, yield 90.8%, purity 99.75%.

Embodiment 3

[0069] Add SM-1 (9.75g, 50mmol) and SM-2 (20.50g, 70mmol) in methanol (80mL), until the materials are completely dissolved, add dropwise a solution of DBU (19.03g, 125mmol) dissolved in methanol (30mL), After the dropwise addition is completed, the temperature is controlled at 45-50°C for 14 hours, the reaction solution is filtered while it is hot, the filtrate is cooled to 0-5°C, stirred and crystallized for 2-3 hours, filtered with suction, and the obtained filter cake is vacuum-dried to obtain pyrazidine intermediate I The compound has a yield of 90.5% and a purity of 99.73%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicine synthesis, and particularly relates to a tipiracil intermediate compound. The synthesis method of the tipiracil intermediate compound comprisesthe following steps: adding SM-1 and SM-2 into an organic solvent, dropwise adding an alkaline solution into a reaction solution, carrying out a temperature-controlled reaction, and filtering to obtain a tipiracil intermediate compound I. The preparation method of the compound is mild in reaction condition, simple in operation process and low in production cost, and the tipiracil prepared from the compound has high purity and yield, and is suitable for industrial production.

Description

technical field [0001] The invention belongs to the field of drug synthesis, in particular to a tipiracil intermediate compound. Background technique [0002] Colorectal cancer (CRC), including colon cancer and rectal cancer, is one of the most common malignant tumors, and its morbidity and mortality rank third among digestive tract malignancies after gastric cancer and esophageal cancer. China is a low-incidence area in the world, but the incidence of colorectal cancer in my country has shown an obvious upward trend in recent years, and it has become one of the fastest-rising malignant tumors in my country. [0003] Due to the lack of obvious early symptoms of colorectal cancer and the lack of early screening measures, most patients have developed to the middle and late stages when they see a doctor. For the treatment of advanced colorectal cancer, the first choice is medical treatment based on chemotherapy. Among them, the new drug Lonsurf (trifluridine (FTD) / hydrochlori...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/553C07D403/06
CPCC07D239/553C07D403/06
Inventor 张贵民赵绪亮胡彦汝
Owner LUNAN PHARMA GROUP CORPORATION
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com